Novo Nordisk alone contributing one-fifth of employment gains to Denmark. But economic headwinds are mounting.

Novo Nordisk’s blockbuster obesity drug Wegovy is set to be greeted by physician enthusiasm and "swift" adoption as it taps into a new liver disease market in the U.S. | Wegovy's mechanism of action ...

Ozempic and Wegovy maker Novo Nordisk stock is down 35% in 2025. The country also said Trump tariffs were hitting the economy ...

In December 2024, Teva also secured FDA approval for the other liraglutide brand Victoza, indicated for type 2 diabetes.

The FDA has approved the first generic GLP-1 specifically indicated for weight loss, according to a press release from Teva Pharmaceuticals. As Healio previously reported, Teva Pharmaceuticals ...

Denmark cuts 2025 growth forecast as Novo Nordisk slowdown and US tariffs raise fears of over-reliance on pharma.

Eli Lilly partners with JD Health to expand in China’s obesity drug market, leveraging digital platforms for growth.

--Denmark cut its 2025 GDP growth forecast to 1.4% from 3% amid weaker prospects for pharmaceutical giant Novo Nordisk and U.S. tariff increases, Bloomberg reports, citing government documents.

Denmark has cut its 2025 economic growth forecast to 1.4% from 3%, citing weaker prospects for pharmaceutical giant Novo ...

Headed by Dr. Aaron Gorin, the plastic surgery firm operates Gorin Plastic Surgery & Med Spa in Tualatin. The suit accused the local firm of mentioning its patented drugs as part of its effort to ...

Novo Nordisk agreed to collaborate with Replicate Biosciences to develop potential new treatments for obesity, type 2 diabetes and other cardiometabolic diseases, as it grapples with mounting ...